Changes of Locomotor Activity by Dopamine D2, D3 Agonist Quinpirole in Mice Using Home-cage Monitoring System

被引:3
|
作者
Park, Jeonghyun [1 ,2 ]
Moon, Eunsoo [1 ,2 ,3 ,6 ,7 ]
Lim, Hyun Ju [1 ,2 ,4 ]
Kim, Kyungwon [1 ,2 ]
Hong, Yoo Rha [5 ]
Lee, Jung Hyun [5 ]
机构
[1] Pusan Natl Univ Hosp, Dept Psychiat, Busan, South Korea
[2] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
[3] Pusan Natl Univ, Sch Med, Dept Psychiat, Yangsan, South Korea
[4] Gyeongsang Natl Univ, Dept Psychol, Jinju, South Korea
[5] Kosin Univ, Coll Med, Dept Pediat, 262 Gamcheon Ro, Busan 49267, South Korea
[6] Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Psychiat, 179 Gudeok Ro, Busan 49241, South Korea
[7] Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Sch Med, 179 Gudeok Ro, Busan 49241, South Korea
关键词
Quinpirole; Dopamine; Infrared detector; Locomotion; Circadian rhythms; INFRARED MOTION DETECTOR; BEHAVIOR; RATS; PREDICTION; RECEPTORS; ONTOGENY; COCAINE;
D O I
10.9758/cpn.22.1016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: As dopamine is closely linked to locomotor activities, animal studies on locomotor activities using dopaminergic agents were widely done. However, most of animal studies were performed for a short period that there is a lack of longitudinal study on the effects of dopaminergic agents on locomotor activities. This study aimed to examine the longterm effect of a dopamine D2, D3 agonist quinpirole on locomotor activities in mice using a home-cage monitoring system. Methods: The locomotor activities of Institute Cancer Research mice were measured by infrared motion detectors in home-cages under the 12-hour dark and 12-hour light condition for three days after the quinpirole injection. Quinpirole was injected at a concentration of 0.5 mg/kg intraperitoneally in the beginning of the dark phase. The locomotor activities before and after the quinpirole administration were compared by the Wilcoxon signed-rank test and one-way repeated measures ANOVA Results: After the quinpirole administration, the 24-hour total locomotor activity did not change (p = 0.169), but activities were significantly increased in the 12-hour dark phase sum (p = 0.013) and decreased in the 12-hour light phase sum (p = 0.009). Significant increases in the activities were observed in the dark-light difference (p = 0.005) and dark-light ratio (p = 0.005) as well. Conclusion: This study suggests that quinpirole injection entrains the circadian rest-activity rhythm of locomotor activities. Therefore, quinpirole can be a drug that mediates locomotor activity as a dopamine agonist as well as a modulator of the circadian rhythms.
引用
收藏
页码:686 / 692
页数:7
相关论文
共 50 条
  • [31] Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats
    Breuer, Megan E.
    Groenink, Lucianne
    Oosting, Ronald S.
    Buerger, Erich
    Korte, Michiel
    Ferger, Boris
    Olivier, Berend
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 616 (1-3) : 134 - 140
  • [32] Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: Role of D2 and D3 dopamine receptors
    Brudzynski, Stefan M.
    Komadoski, Melanie
    St Pierre, Joel
    BEHAVIOURAL BRAIN RESEARCH, 2012, 226 (02) : 511 - 518
  • [33] The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
    Watson, David J. G.
    King, Madeleine V.
    Gyertyan, Istvan
    Kiss, Bela
    Adham, Nika
    Fone, Kevin C. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (02) : 208 - 224
  • [34] Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice
    Lieberknecht, Vicente
    Junqueira, Stella C.
    Cunha, Mauricio P.
    Barbosa, Thais A.
    de Souza, Luiz F.
    Coelho, Igor S.
    Santos, Adair R. S.
    Rodrigues, Ana Lucia S.
    Dafre, Alcir L.
    Dutra, Rafael C.
    MOLECULAR NEUROBIOLOGY, 2017, 54 (02) : 1033 - 1045
  • [35] Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice
    Vicente Lieberknecht
    Stella C. Junqueira
    Mauricio P. Cunha
    Thaís A. Barbosa
    Luiz F. de Souza
    Igor S. Coelho
    Adair R. S. Santos
    Ana Lúcia S. Rodrigues
    Alcir L. Dafré
    Rafael C. Dutra
    Molecular Neurobiology, 2017, 54 : 1033 - 1045
  • [36] MODULATION OF DOPAMINE USING A D2/D3 AGONIST IN PATIENTS WITH BIPOLAR DISORDER: EFFECTS ON COGNITION AND REWARD PROCESSING
    Burdick, Katherine
    Braga, Raphael J.
    Malhotra, Anil K.
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S6 - S6
  • [37] NEUROTENSIN ATTENUATES DOPAMINE D2 AGONIST QUINPIROLE-INDUCED INHIBITION OF MIDBRAIN DOPAMINE NEURONS
    SHI, WS
    BUNNEY, BS
    NEUROPHARMACOLOGY, 1990, 29 (11) : 1095 - 1097
  • [38] Fluorescent ligands for dopamine D2/D3 receptors
    Anni Allikalt
    Nirupam Purkayastha
    Khajidmaa Flad
    Maximilian F. Schmidt
    Alina Tabor
    Peter Gmeiner
    Harald Hübner
    Dorothee Weikert
    Scientific Reports, 10
  • [39] Dopamine D2/D3 receptor availability and venturesomeness
    Bernow, Nina
    Yakushev, Igor
    Landvogt, Christian
    Buchholz, Hans-Georg
    Smolka, Michael N.
    Bartenstein, Peter
    Lieb, Klaus
    Gruender, Gerhard
    Vernaleken, Ingo
    Schreckenberger, Mathias
    Fehr, Christoph
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2011, 193 (02) : 80 - 84
  • [40] Fluorescent ligands for dopamine D2/D3 receptors
    Allikalt, Anni
    Purkayastha, Nirupam
    Flad, Khajidmaa
    Schmidt, Maximilian F.
    Tabor, Alina
    Gmeiner, Peter
    Huebner, Harald
    Weikert, Dorothee
    SCIENTIFIC REPORTS, 2020, 10 (01)